Promising results for Izokibep in PsA
Ph2 RCT meets primary endpoint at Wk 16
ACR50: 13% PBO 48% 40mg IZO 52% 80mg IZO
MDA: 5% PBO 42% 40mg 39% 80mg
Results observed as soon as wk2
No new safety signal compared to IL17Ai
t.co/Gilhg5k36b
Abs#1597 #ACR22 @RheumNow
Achievement of Different Treatment Targets with Izokibep Demonstrates Efficacy Benefits in Patients with Active Psoriatic Arthritis: Results from a 16-Week Randomized, Placebo-Controlled Phase 2 Clinical Trial - ACR Meeting Abstracts
Ph2 RCT meets primary endpoint at Wk 16
ACR50: 13% PBO 48% 40mg IZO 52% 80mg IZO
MDA: 5% PBO 42% 40mg 39% 80mg
Results observed as soon as wk2
No new safety signal compared to IL17Ai
t.co/Gilhg5k36b
Abs#1597 #ACR22 @RheumNow
